Patents by Inventor Leonard I. Zon

Leonard I. Zon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Calmodulin inhibitors, Chk2 inhibitors and RSK inhibitors for the treatment of ribosomal disorders and ribosomapathies
    Patent number: 11944625
    Abstract: The present invention relates to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathies, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to the use of novel classes of compounds, i.e. inhibitors of RSK (p90S6K); inhibitors of p70S6K; and inhibitors of rps6, to treat ribosomal disorders and ribosomopathies. In some embodiments, the invention relates to the use of specific Chk2 inhibitors and to the use of specific phenothiazine derivatives to treat ribosomal disorders and ribosomopathies, e.g. DBA.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: April 2, 2024
    Assignees: THE CHILDREN'S MEDICAL CENTER CORPORATION, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: James Bradner, Jun Qi, Dennis Buckley, Leonard I. Zon, Elizabeth Macari
  • CALMODULIN INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMOPATHIES
    Publication number: 20240091238
    Abstract: The present invention relates generally to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to methods for the use of calmodulin inhibitors and calcium channel blockers for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA).
    Type: Application
    Filed: April 7, 2023
    Publication date: March 21, 2024
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Leonard I. ZON, Alison M. TAYLOR
  • Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomapathies
    Patent number: 11654149
    Abstract: The present invention relates generally to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to methods for the use of calmodulin inhibitors and calcium channel blockers for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA).
    Type: Grant
    Filed: June 21, 2021
    Date of Patent: May 23, 2023
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Leonard I. Zon, Alison M. Taylor
  • CALMODULIN INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMAPATHIES
    Publication number: 20220152041
    Abstract: The present invention relates generally to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to methods for the use of calmodulin inhibitors and calcium channel blockers for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA).
    Type: Application
    Filed: June 21, 2021
    Publication date: May 19, 2022
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Leonard I. ZON, Alison M. TAYLOR
  • CALMODULIN INHIBITORS, CHK2 INHIBITORS AND RSK INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMAPATHIES
    Publication number: 20220008420
    Abstract: The present invention relates to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathies, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to the use of novel classes of compounds, i.e. inhibitors of RSK (p90S6K); inhibitors of p70S6K; and inhibitors of rps6, to treat ribosomal disorders and ribosomopathies. In some embodiments, the invention relates to the use of specific Chk2 inhibitors and to the use of specific phenothiazine derivatives to treat ribosomal disorders and ribosomopathies, e.g. DBA.
    Type: Application
    Filed: February 12, 2021
    Publication date: January 13, 2022
    Applicants: THE CHILDREN'S MEDICAL CENTER CORPORATION, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: James BRADNER, Jun QI, Dennis BUCKLEY, Leonard I. ZON, Elizabeth MACARI
  • Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomapathies
    Patent number: 11065258
    Abstract: The present invention relates generally to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to methods for the use of calmodulin inhibitors and calcium channel blockers for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA).
    Type: Grant
    Filed: August 12, 2019
    Date of Patent: July 20, 2021
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Leonard I. Zon, Alison M. Taylor
  • Calmodulin inhibitors, Chk2 inhibitors and RSK inhibitors for the treatment of ribosomal disorders and ribosomapathies
    Patent number: 10980808
    Abstract: The present invention relates to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathies, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to the use of novel classes of compounds, i.e. inhibitors of RSK (p90S6K); inhibitors of p70S6K; and inhibitors of rps6, to treat ribosomal disorders and ribosomopathies. In some embodiments, the invention relates to the use of specific Chk2 inhibitors and to the use of specific phenothiazine derivatives to treat ribosomal disorders and ribosomopathies, e.g. DBA.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: April 20, 2021
    Assignees: The Children's Medical Center Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: James Bradner, Jun Qi, Dennis Buckley, Leonard I. Zon, Elizabeth Macari
  • METHOD TO ENHANCE TISSUE REGENERATION
    Publication number: 20210077505
    Abstract: The present invention provides for compositions and methods for modulating tissue growth using tissue growth modulators, which are agents that either enhance or inhibit tissue growth as desired by a particular indication by modulating the PG or Wnt signaling pathways, or employing modulators of both PG and Wnt signaling pathways for a synergistic effect or highly selective effect.
    Type: Application
    Filed: June 30, 2020
    Publication date: March 18, 2021
    Applicants: CHILDREN'S MEDICAL CENTER CORPORATION, THE GENERAL HOSPITAL CORPORATION
    Inventors: Leonard I. ZON, Trista E. NORTH, Wolfram GOESSLING
  • ENDOTHELIAL CELL FACTORS AND METHODS THEREOF
    Publication number: 20210079343
    Abstract: The technology described herein relates to compositions and methods of generating endothelial niche cells. Embodiments of the technology described herein comprise compositions, kits, vectors, and methods related to generating or engineering endothelial niche cells. One aspect comprises a method to generate/engineer endothelial niche cells, comprising expressing one or more transcription factors in an endothelial cell, wherein the one or more transcription factors are from the Ets family, the Sox family, and/or the Nuclear Hormone (NHR) family.
    Type: Application
    Filed: March 22, 2019
    Publication date: March 18, 2021
    Applicant: THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Leonard I. ZON, Elliott J. HAGEDORN
  • METHODS FOR INDUCING HEMATOPOIETIC STEM CELL SPECIFICITY
    Publication number: 20200362308
    Abstract: Described herein are methods for inducing HSC specification in a cell. Aspects of the invention relate to contacting a cell with a Runx1-CBF? inhibitor for a specified period of time, and then removing the inhibitor from the cell. In some embodiments of any of the aspects, HSC specificity is maintained long-term.
    Type: Application
    Filed: August 21, 2018
    Publication date: November 19, 2020
    Applicant: THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Leonard I. ZON, Joseph MANDELBAUM
  • Method to enhance tissue regeneration
    Patent number: 10736906
    Abstract: The present invention provides for compositions and methods for modulating tissue growth using tissue growth modulators, which are agents that either enhance or inhibit tissue growth as desired by a particular indication by modulating the PG or Wnt signaling pathways, or employing modulators of both PG and Wnt signaling pathways for a synergistic effect or highly selective effect.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: August 11, 2020
    Assignees: CHILDREN'S MEDICAL CENTER CORPORATION, THE GENERAL HOSPITAL CORPORATION
    Inventors: Leonard I. Zon, Trista E. North, Wolfram Goessling
  • Methods for treatment of adenoid cystic carcinoma
    Patent number: 10668039
    Abstract: The present invention is directed to compositions and methods for treating Adenoid Cystic Carcinoma (ACC).
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: June 2, 2020
    Assignee: THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Leonard I. Zon, Joseph Mandelbaum
  • CALMODULIN INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMAPATHIES
    Publication number: 20200101083
    Abstract: The present invention relates generally to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to methods for the use of calmodulin inhibitors and calcium channel blockers for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA).
    Type: Application
    Filed: August 12, 2019
    Publication date: April 2, 2020
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Leonard I. ZON, Alison M. TAYLOR
  • CALMODULIN INHIBITORS, CHK2 INHIBITORS AND RSK INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMAPATHIES
    Publication number: 20190314374
    Abstract: The present invention relates to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathies, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to the use of novel classes of compounds, i.e. inhibitors of RSK (p90S6K); inhibitors of p70S6K; and inhibitors of rps6, to treat ribosomal disorders and ribosomopathies. In some embodiments, the invention relates to the use of specific Chk2 inhibitors and to the use of specific phenothiazine derivatives to treat ribosomal disorders and ribosomopathies, e.g. DBA.
    Type: Application
    Filed: July 13, 2017
    Publication date: October 17, 2019
    Applicants: The Children's Medical Center Corporation, Dana-Faber Cancer Institute, Inc.
    Inventors: James BRADNER, Jun QI, Dennis BUCKLEY, Leonard I. ZON, Elizabeth MACARI
  • Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomapathies
    Patent number: 10420778
    Abstract: The present invention relates generally to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to methods for the use of calmodulin inhibitors and calcium channel blockers for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA).
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: September 24, 2019
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Leonard I. Zon, Alison M. Taylor
  • METHODS FOR TREATMENT OF ADENOID CYSTIC CARCINOMA
    Publication number: 20190192468
    Abstract: The present invention is directed to compositions and methods for treating Adenoid Cystic Carcinoma (ACC).
    Type: Application
    Filed: September 1, 2017
    Publication date: June 27, 2019
    Inventors: Leonard I. ZON, Joseph MANDELBAUM
  • Methods for promoting hematopoietic reconstitution
    Patent number: 10278990
    Abstract: The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E2 (PGE2) and agents that stimulate the PGE2 pathway. Conversely, HSC modulators that prevent PGE2 synthesis decrease HSC numbers. HCS modulators may be used in vitro, in vivo, or ex vivo.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: May 7, 2019
    Assignees: Children's Medical Center Corporation, The General Hospital Corporation
    Inventors: Leonard I. Zon, Trista E. North, Wolfram Goessling
  • Methods for promoting HSC engraftment
    Patent number: 10272110
    Abstract: The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E2 (PGE2) and agents that stimulate the PGE2 pathway. Conversely, HSC modulators that prevent PGE2 synthesis decrease HSC numbers. HCS modulators may be used in vitro, in vivo, or ex vivo.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: April 30, 2019
    Assignees: Children's Medical Center Corporation, The General Hospital Corporation
    Inventors: Leonard I. Zon, Trista E. North, Wolfram Goessling
  • Methods for enhancing hematopoietic stem/progenitor cell engraftment
    Patent number: 10159697
    Abstract: Described herein are methods for enhancing engraftment of hematopoietic stem and progenitor cells using farnesyl compounds identified using a zebrafish model of hematopoietic cell engraftment. The compounds can be used to treat hematopoietic stem cells ex vivo prior to transplantation of the cells. Alternatively, the compounds can be administered to an individual undergoing cell transplantation.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: December 25, 2018
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Leonard I. Zon, Pulin Li
  • Methods for enhancing hematopoietic stem/progenitor cell engraftment
    Patent number: 10092599
    Abstract: Described herein are methods for enhancing engraftment of hematopoietic stem and progenitor cells using compounds identified using a zebrafish model of hematopoietic cell engraftment. The compounds can be used to treat hematopoietic stem cells ex vivo prior to transplantation of the cells. Alternatively, the compounds can be administered to an individual undergoing cell transplantation.
    Type: Grant
    Filed: May 7, 2015
    Date of Patent: October 9, 2018
    Assignee: Children's Medical Center Corporation
    Inventors: Leonard I. Zon, Pulin Li